<code id='170EAC6CE5'></code><style id='170EAC6CE5'></style>
    • <acronym id='170EAC6CE5'></acronym>
      <center id='170EAC6CE5'><center id='170EAC6CE5'><tfoot id='170EAC6CE5'></tfoot></center><abbr id='170EAC6CE5'><dir id='170EAC6CE5'><tfoot id='170EAC6CE5'></tfoot><noframes id='170EAC6CE5'>

    • <optgroup id='170EAC6CE5'><strike id='170EAC6CE5'><sup id='170EAC6CE5'></sup></strike><code id='170EAC6CE5'></code></optgroup>
        1. <b id='170EAC6CE5'><label id='170EAC6CE5'><select id='170EAC6CE5'><dt id='170EAC6CE5'><span id='170EAC6CE5'></span></dt></select></label></b><u id='170EAC6CE5'></u>
          <i id='170EAC6CE5'><strike id='170EAC6CE5'><tt id='170EAC6CE5'><pre id='170EAC6CE5'></pre></tt></strike></i>

          knowledge

          knowledge

          author:knowledge    Page View:51
          John-Arne-Røttingen, a white man with short hair, smiles at the camera wearing blue suits — biotech coverage from STAT
          John-Arne Røttingen is the head of the Wellcome Trust, one of the world’s top private funders of biomedical research. Illustration: STAT; Source: Wellcome Trust

          LONDON — The key groups involved in addressing global health problems often include governments, foundations, and pharmaceutical companies.

          But to John-Arne Røttingen, the new head of the Wellcome Trust, one of the world’s top private funders of biomedical research, there’s another sector that should be getting involved — the tech industry.

          advertisement

          The Alphabets and Amazons of the world have been growing their health-related initiatives, but the industry is rarely mentioned when neglected public health issues are discussed, Røttingen argued.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more
          New rules on organ donation and transplantation 'will bring chaos'
          New rules on organ donation and transplantation 'will bring chaos'

          OrgandonationpaperworkatMid-AmericaTransplantServicesinSt.Louis.WhitneyCurtis/APTheUnitedStateshadao

          read more
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
          Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

          6:16PresidentJoeBidenspeaksintheRooseveltRoomoftheWhiteHouse,June30,2023.EvanVucci/APPresidentJoeBid

          read more

          AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

          RubyWallauforSTATAbbViewillpay$10billionforthebiotechfirmImmunogen,thecompanysaidThursday,acquiringa